Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents
The present disclosure relates to novel cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, the disclosure relates to novel tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer.
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof
wherein:
R 1 is hydrogen;
M is N;
L is O;
A is CR 5 ;
W is CR 6 ;
R 2 , R 5 and R 6 are independently hydrogen, C 1-6 alkyl, or halo;
X, Y, and Z are CH; and
R 3 and R 4 are independently hydrogen, halo, C 1-6 haloalkyl or C 1-6 haloalkoxy.
2. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
3. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
4. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
5. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
6. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
7. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
8. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
9. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
10. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.
11. The compound according to claim 1 , having following structure:
or pharmaceutically acceptable salts thereof.